Bone turnover in elderly females and males using bisphosphonate treatment - A pilot study

B. L. Gulson; K. J. Mizon; H. Smith; J. Eisman; J. M. Palmer; M. J. Korsch; J. Donnelly; K. Waite

Bone turnover in elderly females and males using bisphosphonate treatment - A pilot study

B. L. Gulson^*, K. J. Mizon, H. Smith, J. Eisman, J. M. Palmer, M. J. Korsch, J. Donnelly, K. Waite

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We undertook a 2 year pilot study in premenopausal and postmenopausal females and male partners in which the subjects were administered a biphosphonate, for 6 months. The aim of the study was to determine how lead isotopes and lead concentrations changed in relation to bone remodelling processes. Each subject had blood and urine samples collected for markers of bone turnover and for lead isotope studies monthly for 7 - 9 months before and then 3 monthly during and for up to 6 months after treatment with alendronate as an agent for inhibiting bone resorption. There were significant decreases in the lead isotope ratio, ²⁰⁶Pb/²⁰⁴Pb, for the migrant subjects during treatment compared with pre-treatment period (p<0.01). The average blood lead concentrations in migrant subjects decreased by about 20% during the treatment compared with the pre-treatment period (p<0.01). The changes in lead isotopic composition and lead concentration are consistent with a decrease in bone resorption and associated mobilisation of lead during alendronate therapy.

Original language	English
Pages (from-to)	601-604
Number of pages	4
Journal	Journal De Physique. IV : JP
Volume	107
Issue number	I
Publication status	Published - May 2003

Cite this

@article{c240d57d0afb49dbaa3ced0b02424dd5,

title = "Bone turnover in elderly females and males using bisphosphonate treatment - A pilot study",

abstract = "We undertook a 2 year pilot study in premenopausal and postmenopausal females and male partners in which the subjects were administered a biphosphonate, for 6 months. The aim of the study was to determine how lead isotopes and lead concentrations changed in relation to bone remodelling processes. Each subject had blood and urine samples collected for markers of bone turnover and for lead isotope studies monthly for 7 - 9 months before and then 3 monthly during and for up to 6 months after treatment with alendronate as an agent for inhibiting bone resorption. There were significant decreases in the lead isotope ratio, 206Pb/204Pb, for the migrant subjects during treatment compared with pre-treatment period (p<0.01). The average blood lead concentrations in migrant subjects decreased by about 20% during the treatment compared with the pre-treatment period (p<0.01). The changes in lead isotopic composition and lead concentration are consistent with a decrease in bone resorption and associated mobilisation of lead during alendronate therapy.",

author = "Gulson, {B. L.} and Mizon, {K. J.} and H. Smith and J. Eisman and Palmer, {J. M.} and Korsch, {M. J.} and J. Donnelly and K. Waite",

year = "2003",

month = may,

language = "English",

volume = "107",

pages = "601--604",

journal = "Journal De Physique IV",

issn = "1155-4339",

publisher = "EDP Sciences",

number = "I",

}

TY - JOUR

T1 - Bone turnover in elderly females and males using bisphosphonate treatment - A pilot study

AU - Gulson, B. L.

AU - Mizon, K. J.

AU - Smith, H.

AU - Eisman, J.

AU - Palmer, J. M.

AU - Korsch, M. J.

AU - Donnelly, J.

AU - Waite, K.

PY - 2003/5

Y1 - 2003/5

N2 - We undertook a 2 year pilot study in premenopausal and postmenopausal females and male partners in which the subjects were administered a biphosphonate, for 6 months. The aim of the study was to determine how lead isotopes and lead concentrations changed in relation to bone remodelling processes. Each subject had blood and urine samples collected for markers of bone turnover and for lead isotope studies monthly for 7 - 9 months before and then 3 monthly during and for up to 6 months after treatment with alendronate as an agent for inhibiting bone resorption. There were significant decreases in the lead isotope ratio, 206Pb/204Pb, for the migrant subjects during treatment compared with pre-treatment period (p<0.01). The average blood lead concentrations in migrant subjects decreased by about 20% during the treatment compared with the pre-treatment period (p<0.01). The changes in lead isotopic composition and lead concentration are consistent with a decrease in bone resorption and associated mobilisation of lead during alendronate therapy.

AB - We undertook a 2 year pilot study in premenopausal and postmenopausal females and male partners in which the subjects were administered a biphosphonate, for 6 months. The aim of the study was to determine how lead isotopes and lead concentrations changed in relation to bone remodelling processes. Each subject had blood and urine samples collected for markers of bone turnover and for lead isotope studies monthly for 7 - 9 months before and then 3 monthly during and for up to 6 months after treatment with alendronate as an agent for inhibiting bone resorption. There were significant decreases in the lead isotope ratio, 206Pb/204Pb, for the migrant subjects during treatment compared with pre-treatment period (p<0.01). The average blood lead concentrations in migrant subjects decreased by about 20% during the treatment compared with the pre-treatment period (p<0.01). The changes in lead isotopic composition and lead concentration are consistent with a decrease in bone resorption and associated mobilisation of lead during alendronate therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037701436&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037701436

VL - 107

SP - 601

EP - 604

JO - Journal De Physique IV

JF - Journal De Physique IV

SN - 1155-4339

IS - I

ER -

Bone turnover in elderly females and males using bisphosphonate treatment - A pilot study

Abstract

Other files and links

Fingerprint

Cite this